Instalab
logoInstalab

Glycocholic Acid

Stool Test
Catch hidden liver stress and bile flow problems before standard liver enzymes look abnormal.
4.9 (2,916 reviews)
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Collect your sample
At home
Get results
Explained with clear next steps, no medical jargon

Should you take a GCA test?

This test is most useful if any of these apply to you.

Worried About Your Liver
This test gives a more sensitive read on liver and bile flow than standard enzymes, often catching shifts before ALT and AST move.
Drinking More Than You'd Like
Heavy alcohol use raises this marker substantially and tracks liver damage severity, giving an objective signal of how your liver is coping.
Pregnant With Persistent Itching
Itching late in pregnancy can signal intrahepatic cholestasis, where this marker rises sharply and helps confirm the diagnosis with high accuracy.
Watching Your Metabolic Health
Higher levels predict future type 2 diabetes years before blood sugar shifts, adding an early signal that fasting glucose alone misses.

About Glycocholic Acid

Your liver makes bile acids constantly to help you digest fat, and it normally pulls almost all of them back out of your blood before they can build up. When that recycling system gets disrupted by liver injury, blocked bile flow, or metabolic stress, GCA (glycocholic acid) starts leaking into your bloodstream and rising. That makes it a sensitive early signal of trouble in your liver and bile ducts.

This is a research-stage marker, not a routine clinical test. Standardized cutpoints do not yet exist outside of pregnancy-related cholestasis. But the data linking elevated GCA to liver cancer, alcoholic liver disease, fatty liver, and incident type 2 diabetes is strong enough that getting a baseline and tracking your trend can give you a head start on problems that standard liver enzymes often miss.

What This Bile Acid Actually Does

GCA is a glycine-conjugated primary bile acid. Your liver builds it by attaching the amino acid glycine to cholic acid, then secretes it into bile. In your gut, GCA acts like a detergent that breaks dietary fat into droplets small enough for your body to absorb, and it also helps activate the enzymes that digest those fats.

Most of the GCA you make gets reabsorbed in your small intestine and pulled back to the liver through a recycling loop called enterohepatic circulation. In a healthy person, less than 1% escapes into your general bloodstream, with fasting serum levels typically below 2.5 mg/L. When liver cells are damaged or bile gets backed up, that tight recycling breaks down and GCA spills into your blood at much higher concentrations.

Liver Disease Risk

GCA is one of the most consistent bile acid markers of liver injury across the published literature. In a study of 645 people, conjugated bile acids including GCA discriminated people with liver impairment from healthy people better than unconjugated bile acids, with GCA reaching an area under the curve of 0.882 for detecting liver injury (AUC of 0.5 means a coin flip; 1.0 means perfect detection).

In hepatitis B-related cirrhosis, serum GCA rises in step with disease severity tracked by Child-Pugh stage. In alcoholic cirrhosis, GCA was elevated roughly 22-fold compared to controls and tracked clinical severity scores. Fasting serum GCA also climbs progressively across acute hepatitis, chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Liver Cancer Risk

This is where the prospective evidence is strongest. In the Finnish ATBC cohort, which followed people for up to 27 years before they developed disease, those in the highest quartile of pre-diagnostic serum GCA were about 5.3 times as likely to develop liver cancer (OR 5.30, 95% CI 2.41 to 11.66) and about 7 times as likely to die from liver disease (OR 6.98, 95% CI 3.32 to 14.68) compared to those in the lowest quartile, after adjusting for age, education, diabetes, smoking, alcohol, and BMI.

A pooled analysis across 12 US cohorts with 872 liver cancer cases found that each doubling of GCA was associated with about 32% higher liver cancer risk (OR 1.32, 95% CI 1.24 to 1.40). In Taiwanese REVEAL studies of people with chronic hepatitis B and C, those in the top GCA quartile had roughly 3.4 times the risk of hepatocellular carcinoma in the hepatitis B group and about 8 times the risk in the hepatitis C group.

What this means for you: if you have any chronic liver risk factor like hepatitis, heavy alcohol exposure, or fatty liver, GCA gives you a long-lead-time window into cancer risk that standard ALT and AST checks do not provide.

Fatty Liver Disease

In a meta-analysis of metabolic dysfunction-associated steatotic liver disease (the condition formerly called NAFLD), GCA and other conjugated bile acids were consistently elevated compared to healthy controls. Higher levels also tracked with more advanced fibrosis as measured by the ELF (Enhanced Liver Fibrosis) score. In children with fatty liver, postprandial bile acid patterns including GCA changed in ways that may eventually serve as non-invasive markers of disease progression.

Type 2 Diabetes Risk

In the 4C Study, a Chinese cohort of 54,807 adults with normal blood sugar at baseline followed for a median of about 3 years, conjugated primary bile acids including GCA each carried roughly 11% to 19% higher risk of developing diabetes per standard deviation increase. The associations held up after adjustment for liver enzymes, HDL, diet, 2-hour glucose, insulin resistance, and waist circumference, suggesting GCA captures something beyond what those standard tests reveal.

Colorectal Cancer Risk

In the European EPIC cohort, women in the highest quartile of pre-diagnostic GCA had about 2.2 times the risk of colon cancer compared to the lowest quartile (OR 2.22, 95% CI 1.52 to 3.26) after adjusting for education, physical activity, smoking, body fat, and detailed diet. A US analysis (ATBC and PLCO) found a similar pattern in women, with GCA in the top quartile linked to about 2.3 times the colorectal cancer risk.

Pregnancy: Intrahepatic Cholestasis

In pregnant women, sustained itching and elevated bile acids can signal intrahepatic cholestasis of pregnancy, a condition that increases the risk of preterm birth. Maternal serum GCA is markedly elevated in this condition and discriminates affected pregnancies from healthy ones with very high accuracy (AUC 0.985 in the third trimester). When combined with two other markers in a panel, accuracy reaches 0.993. Early-onset cases tend to show GCA dominance, and the proportion of total bile acids made up of GCA helps predict preterm birth risk.

Reference Ranges

There are no consensus clinical cutpoints for GCA outside of pregnancy. The values below come from a single study of 314 healthy adults measured by a high-precision lab method that combines liquid chromatography with mass spectrometry. Asians had significantly higher GCA than Caucasians, and women trended slightly higher than men, though not always significantly so. Treat these as orientation, not a target. Your lab will likely report different numbers, possibly in different units.

GroupMean GCA (ng/mL)10th to 90th percentile (ng/mL)
Men under 40192.534.0 to 509.9
Men 40 to 60181.332.8 to 303.2
Women under 40346.331.2 to 595.4
Women 40 to 60209.327.7 to 418.3

Source: Luo et al. 2018, PLOS ONE, healthy reference cohort. Compare your results within the same lab over time for the most meaningful trend, since assays vary between labs.

Tracking Your Trend

GCA reflects a dynamic process, not a fixed trait. The same person can show meaningful shifts based on liver health, alcohol exposure, weight gain or loss, and bile flow patterns. A single value tells you where you sit today; a trend tells you whether your liver and bile system are stable, improving, or quietly deteriorating.

Get a baseline now, then retest in 3 to 6 months if you are making lifestyle changes that affect the liver, and at least annually thereafter. If your value lands in the upper end of published reference ranges or rises noticeably between draws, that pattern is more useful than any single number for prompting deeper investigation.

What to Do With an Elevated Result

An isolated high GCA does not diagnose any specific condition, but it is a strong signal to look at your liver more carefully. The right next step depends on context: pair it with standard liver chemistry (ALT, AST, ALP, GGT, bilirubin), an albumin and platelet check, hepatitis B and C screening if you have not been tested, and a fasting lipid and metabolic panel.

If GCA is high alongside elevated ALT or AST, an evaluation for fatty liver disease (often with imaging like ultrasound or MRI-based fibrosis assessment) is reasonable. If you have known chronic hepatitis or heavy alcohol exposure, an elevated GCA should push you toward hepatology consultation, since the prospective data link high GCA to substantially higher long-term liver cancer risk. In pregnancy with itching, an elevated GCA alongside high total bile acids supports a diagnosis of intrahepatic cholestasis and warrants obstetric management.

When Results Can Be Misleading

GCA varies meaningfully with timing and context. The most common sources of distortion:

  • Recent meals: GCA rises sharply after eating because bile is released to digest fat. Reference ranges are based on fasting samples. Test fasting to make trends comparable.
  • Pregnancy: Normal pregnancy alters bile acid metabolism and can shift GCA upward. Pregnancy reference ranges differ from non-pregnant ones.
  • Acute illness or infection: Any acute hepatic stress can transiently raise bile acids. If you have a recent illness, surgery, or fever, retest after recovery rather than acting on a single elevated value.
  • Ethnicity-related baseline differences: Asian populations show significantly higher baseline GCA than Caucasian populations in healthy reference cohorts. A value that looks elevated against one population's range may be normal for another.

Frequently Asked Questions

References

19 studies
  1. Wang X, Xie G, Zhao a, Zheng X, Huang F, Wang Y, Yao C, Jia W, Liu PJournal of Proteome Research2016
  2. Yang Z, Kusumanchi P, Ross RA, Heathers L, Chandler K, Oshodi a, Thoudam T, Li F, Wang L, Liangpunsakul SHepatology Communications2019
  3. Kalhan S, Guo L, Edmison JM, Dasarathy S, Mccullough a, Hanson R, Milburn MMetabolism: Clinical and Experimental2011